- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05955625
TIMELY: a Patient-centred Lifestyle Program for Patients With Coronary Artery Disease (TIMELY)
TIMELY: A Patient-centred Lifestyle Program to Support the Continuum of Care in Patients With Coronary Artery Disease Using eHealth and Artificial Intelligence
Study design: A randomized controlled trial will be used, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group in which patients will receive usual care in combination with the TIMELY intervention for a duration of 6 months.
Study sample: Female and male patients aged 18 years or over, with documented stable CAD and referred for cardiac rehabilitation (at > 2 weeks but <10 weeks after PCI or >4 weeks but <12 weeks after CABG or MI: STEM or non-STEMI), and/or having documented CAD by coronary angiography (stenosis in a major coronary artery >50%).
Intervention: Patients randomized to the intervention group will receive the TIMELY app on their phones or tablets for 6 months. Patients will also receive a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviors and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviors during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
Main study parameters/endpoints: The primary biomedical outcome is a change in the CoroPredict biomarker risk score from baseline (pre-randomization) to completion of the active intervention phase (6 months). The CoroPredict score is an indicator of the 10-year risk of mortality. The primary behavioral outcome is the change from baseline to 6 months in patients' functional status of fitness level (measured using the 6-minute walk test). The study further aims to improve secondary outcome measures: physical activity levels during daily life and cardiovascular responses to exercise, dietary habits, smoking behavior, medication adherence and perceived levels of psychological stress.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background of the study:
Cardiovascular diseases (CVD) are the leading cause of death globally according to the WHO. The highest burden of disease among CVDs is caused by coronary artery disease (CAD). Ageing predisposes patients to a high incidence and prevalence of CAD, in both men and women. Older patients have the greatest mortality and morbidity risk attributable to Chronic Coronary Syndromes (CCS), partially due to the high prevalence of comorbidities. Secondary prevention through comprehensive cardiac rehabilitation (CR) has been recognized as the most cost-effective intervention to limit the physiological and psychological effects of CVDs and reduce the risk of future cardiovascular events.
Contrary to pharmacological or invasive interventions for CAD, CR is far from being well implemented in all European countries and participation rates in available programs range between 30-50% of eligible patients. The TIMELY platform has been developed to stimulate a healthy lifestyle after CR. Patient-related barriers for digital health mainly involve the usability of the CR platform, especially for older patients. Thus, TIMELY includes digital tools and interfaces that will not hinder senior citizens from using them, as patient co-design has guided the development. Since lifestyle changes are key in the prevention and self-management of CAD, the main component of the TIMELY platform will be an app built on behavioral change techniques and models to empower and motivate patients to adopt a healthy lifestyle. Artificial intelligence (AI) will be employed to adapt the platform to the most current needs of the patient. In addition to prevention and self-management, the TIMELY platform will constantly monitor and predict the individual risk for disease progression or serious events and complications using validated risk scores (CoroPredict®). TIMELY will become the first AI-powered, patient-centered eHealth platform that continuously adapts and customizes CR to meet the needs of patients.
Objective of the study:
1. To investigate whether the TIMELY intervention is superior to usual care in terms of A) reducing the CoroPredict risk score (indicating risk of 10-year mortality: primary biomedical outcome) from baseline to six months; and B) increasing functional fitness levels (6-minute walk test); primary behavioral outcome) from baseline to 6 months
Study design:
A randomized controlled trial study design will be employed, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group, where patients will receive usual care in combination with the TIMELY intervention.
Assessment will take place at 4 time points: baseline, 3, 6 and 12 months post inclusion.
Patients will be asked to fill out questionnaires at 4 timepoints: baseline, 3 months, 6 months and 12 months. Through the TIMELY-platform (app) patients in the intervention group will receive prompts to conduct and ECG and blood pressure measurement. Patient in the intervention group will be wearing a Garmin, which collects information about their physical activity patterns. Lastly, patients will receive physical assessments at three time points (baseline, 6 months and 12 months), namely an exercise test and bloodwork will be done.
Study population:
Patients with documented CAD and who have been referred to cardiac rehabilitation (at > 2 weeks but < 10 weeks after PCI or > 4 weeks but <12 weeks after CABG or MI: STEMI or non-STEMI), and/or have documented CAD by coronary angiography (stenosis in a major coronary artery > 50%) will be included. Recruitment will set special focus on women, recruiting racial/ethnic minorities, older adults, rural residents, and economically disadvantaged individuals.
Intervention:
Timely app:
The TIMELY app will help patients adjust their lifestyle in order for them to become healthier. The TIMELY app is supported by artificial intelligence and is based on behavioral change techniques. Through the chatbots the messages aimed at changing the behavior of patients will be personalized. Specific attention will be given to promoting physical activity. Because the chatbots can take the (physical) context of the patient into account, the odds of success are higher.
Wrist-worn activity tracker:
Patients will receive an activity tracker, which will collect physical measures, such as level of activity, heart rate and sleep.
Tel-O-Graph:
Patients will receive a blood pressure monitor, the Tel-O-Graph. The device additionally measures other hemodynamic parameters through pulse wave analysis (PWA).
Net_ECG:
Patients will receive an easy-to-use device capable of registering atrial fibrillation.
- eConnect HUB: Patients will receive the eConnect HUB which will transfer all data from the Tel-O-Graph to the researchers.
Patients will complete questionnaires at 4 timepoints: baseline, 3 months, 6 months and 12 months. In addition, patients will have conversations with the chatbots in the app and, based on this, receive encouragement to perform certain behaviors (e.g., exercise more or eat healthier). Through the TIMELY platform (app), patients will receive messages to take their ECG and blood pressure readings. Furthermore, patients will wear a Garmin, which will collect information about their exercise behavior. Finally, at the three measurement moments, patients will receive an exercise test. Blood will also be drawn at these times.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Germany
-
Ennepetal, Germany, Germany, 58256
- Klinik Königsfeld
-
-
-
-
North Brabant
-
Tilburg, North Brabant, Netherlands, 5037 AB
- Willem Johan Kop
-
-
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spain, 15706
- Hospital Universitario de Santiago de Compostela
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and over (there is no a priori upper age limit)
- Documented stable CAD and referred for cardiac rehabilitation (at > 2 weeks but < 10 weeks after PCI or > 4 weeks but <12 weeks after CABG or MI: STEMI or non-STEMI) and/or having documented CAD by coronary angiography (stenosis in a major coronary artery > 50%)
- Access and ability to operate a smartphone
- Able to speak the country's native language
Exclusion Criteria:
- Unable to fully understand the provided study information and consequences of participating in the study
- Presence of a physical impairment interfering with the use of the app or devices (e.g., blindness, wheelchair bound)
- Known diagnosis of an active malignant tumour (cancer) or any other medical condition associated with a life expectancy of less than one year
- Unstable cardiovascular, cerebrovascular or other unstable medical condition
- Refusal to informed consent
- Having a pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TIMELY intervention and care as usual
The intervention group will receive the TIMELY intervention including wearable monitoring devices and app in addition to care as usual for a duration of 6 months.
|
The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics.
Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life.
In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
|
|
No Intervention: Care as usual
The care as usual group will receive the standard care as they would receive without being enrolled in the current trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in functional fitness levels
Time Frame: Baseline and 6 months
|
Functional fitness levels will be assessed using the 6-minute walking test, using the number of meters walked as the outcome.
|
Baseline and 6 months
|
|
Change in risk of mortality
Time Frame: Baseline and 6 months
|
Risk of mortality will be determined using the validated biomarker risk score CoroPredict, indicating 10-year mortality probability.
|
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cardiovascular exercise tolerance
Time Frame: Baseline and 6 months
|
Measures of cardiovascular responses to exercise will be based on graded symptom-limited exercise tests, using maximum watt as the outcome
|
Baseline and 6 months
|
|
Change in weight
Time Frame: Baseline and 6 months
|
Weight will be measured in kilograms
|
Baseline and 6 months
|
|
Change in physical activity
Time Frame: Baseline, 3 months and 6 months
|
Physical activity will be measured by the validated International Physical Activity Questionnaire (IPAQ), a total score of MET minutes can be calculated.
|
Baseline, 3 months and 6 months
|
|
Change in healthy dietary habits
Time Frame: Baseline, 3 months and 6 months
|
Dietary habits will be assessed using the dietary questions from the validated Health Promoting Lifestyle Profiles-II questionnaire.
Scores range from 9 to 36, with a higher score indicating better dietary habits.
|
Baseline, 3 months and 6 months
|
|
Change in smoking cessation
Time Frame: Baseline, 3 months and 6 months
|
Smoking cessation will be assessed by the validated Fagerström test.
Scores range from 0-10 with a higher score indicating higher nicotine dependence.
|
Baseline, 3 months and 6 months
|
|
Change in medication adherence
Time Frame: Baseline, 3 months and 6 months
|
Medication adherence will be assessed using the validated Medication Adherence Report Scale (MARS-5) questionnaire.
Scores range from 5 to 25, with a higher score indicating higher medication adherence.
|
Baseline, 3 months and 6 months
|
|
Change in psychological stress levels
Time Frame: Baseline, 3 months, 6 months
|
Psychological stress will be measured using validated the Perceived Stress Score questionnaire (PSS-10).
Scores range from 0 to 40, with a higher score indicating higher levels of perceived stress.
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jos Bosch, PhD, University of Amsterdam
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Infarction
- Necrosis
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Ischemia
- Pathological Conditions, Signs and Symptoms
- Behavior
- Coronary Artery Disease
- Myocardial Infarction
- Motor Activity
Other Study ID Numbers
- NL82723.028.23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Beijing Northland Biotech. Co., Ltd.Not yet recruitingAcute Myocardial Infarction (AMI) | Acute Myocardial Infarction of Anterior Wall | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction With ST Segment Elevation | Acute Myocardial Infarction of Left VentricleChina
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SAWithdrawn
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Harbin Medical UniversityNot yet recruitingNon-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)Acute Myocardial Infarction (AMI) | ST-Segment Elevation Myocardial Infarction(STEMI) | Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)China
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationCompletedST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionUnited States, Spain, Netherlands, Canada, Australia, Serbia, Egypt, Switzerland, Hungary, United Kingdom, France, Czechia, Nepal, North Macedonia
-
Chonnam National University HospitalNot yet recruitingMyocardial Infarction (MI) | AF - Atrial Fibrillation | NSTEMI - Non-ST-Segment Elevation Myocardial Infarction | ST-Segment Elevation Myocardial Infarction(STEMI)South Korea
Clinical Trials on TIMELY
-
VA Office of Research and DevelopmentDurham VA Health Care System; William S. Middleton Memorial Veterans HospitalNot yet recruitingHead and Neck Cancer | Dysphagia | Hearing Loss | TinnitusUnited States
-
Pontificia Universidad Catolica de ChileCompletedUrologic Diseases | Frail Elderly Syndrome | Surgery | Anesthesia | Nurse-Patient Relations | Perioperative Care | Older Adults | Old Age; Debility | Post-Operative Confusion | Digestive DiseaseChile
-
Hackensack Meridian HealthWithdrawn
-
Geisinger ClinicCompletedHealth Behavior | TelehealthUnited States
-
RANDNational Institute of Mental Health (NIMH); Arizona State University; Mildmay...RecruitingHIV/AIDS | Medication Adherence | HabitsUganda
-
Northwestern UniversityRecruitingAcute Lymphoblastic Leukemia | Lymphoblastic LymphomaUnited States
-
James Graham Brown Cancer CenterUniversity of LouisvilleCompleted
-
RANDNational Institute of Mental Health (NIMH); Arizona State University; Mildmay...Completed
-
Lifespan Healthcare Resource LimitedBill and Melinda Gates FoundationUnknown
-
National Defense Medical Center, TaiwanNot yet recruiting